LOS ANGELES, Aug. 19, 2004 (PRIMEZONE) -- Universal Detection Technology (OTCBB:UDTT) ("the Company") announced today that it has retained KAL Consultants, Inc., Deerfield Beach, Florida to assist with the Company's marketing and sales efforts of its anthrax "smoke" detector technology.
"We are extremely pleased to assist in bringing UDT's unique technology to full-scale market implementation," said Bill Kramer, President of KAL Consultants. "We share the Company's vision of providing public and municipal buildings a first-line of defense against bio-terrorism."
During the next several months, the Company plans to engage in field testing of its Anthrax Smoke Detector in different environments and conditions and to use the empirical data gained from the testing to further improve the design and functionality of the product. The Company plans to initiate orders of the Anthrax Smoke Detector with a third-party manufacturer based on sales orders it receives.
"The experience KAL Consultants brings to the Company is welcomed. I am confident that our new relationship with KAL Consultants will bring value-added benefits to our current marketing efforts by focusing on introducing this technology to the commercial and government sectors," concluded Jacques Tizabi, President of Universal Detection.
About KAL Consultants
KAL Consultants, Inc. is a full service business development firm that specializes in bringing emerging growth companies to market in energy, technology, biomedical, chemical and process engineering, communications, information services, and Homeland Security applications. KAL has represented clients primarily in the Washington, D.C. metropolitan area, Florida, and California. In addition to marketing and sales, the company also provides expertise in the preparation of detailed business plans, preparation of business proposals for government, industry, and technical applications, business finance and capitalization requirements, optimization of manufacturing and operating processes, intellectual property and seminal patent development, and conceptualization and implementation of new business strategies.
The company's staff encompasses over 50 years combined experience in corporate management, marketing, and sales ranging from NASDAQ-listed public companies to start-up developmental companies, and has established high-level relationships within several sectors of government, including: The Department of Homeland Security, The Small Business Administration, the Department of Education, The State Department, The Department of Defense and The Florida and California Senate and House of Representatives.
Past clients include: Spherical Dynamics, Thinking Craft, The National Safety Transportation Council and The National Children's Foundation.
About Universal Detection Technology
Universal Detection Technology (UDT), founded in 1973, is a developer of monitoring technologies, including bio-terrorism detection devices. Management believes that the Company's technology, together with third-party technologies and devices, has positioned it to capitalize on growth and value opportunities related to Homeland Security. Universal Detection Technology, in cooperation with NASA's Jet Propulsion Laboratory (JPL), has developed a bio-terror 'smoke' detector, which combines JPL's spore detection technology with UDT's aerosol capture device. For more information, please visit: (http://udtt.invrel.net) or (http://www.udetection.com).
Safe Harbor
Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties include, among other things, the funding of amounts of capital adequate to provide for the working capital needs of the Company, our ability to timely and cost effectively complete the development of our products targeted to the bio-chemical and medical markets, commercial acceptance of our products, product price volatility, product demand, market competition and general economic conditions, and other factors described in the Company's filings with the Securities and Exchange Commission. We undertake no obligation and do not intend to revise or update publicly any forward looking statements for any reason.